中华放射肿瘤学杂志
Friday, Apr. 4, 2025   Home | Journal | Editorial | Instruction | Subscription | Advertisement | Academic | Index-in | Contact Us | Chinese
Chinese Journal of Radiation Oncology  2020, Vol. 29 Issue (6): 416-420    DOI: 10.3760/cma.j.cn113030-20190325-00107
Thoracic Tumors Current Issue| Next Issue| Archive| Adv Search [an error occurred while processing this directive] | [an error occurred while processing this directive]
Experience and efficacy of SBRT for lung cancer:an analysis of 142 patients
Dong Baiqiang, Wang Jin, Xu Yujin, Hu Xiao, Du Xianghui, Shan Guoping, Shao Kainan, Bai Xue, Chen Ming
Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences; Department of Radiation Oncology,Cancer Hospital of the University of Chinese Academy of Sciences; Department of Radiation Oncology, Zhejiang Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou 310022, China
Download: PDF (0 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      Supporting Info
Abstract  Objective To evaluate the clinical efficacy and safety of stereotactic body radiation therapy (SBRT) for stage Ⅰ-Ⅱ non-small cell lung cancer. Methods Retrospective analysis of patients with early stage lung cancer who received SBRT in Zhejiang Cancer Hospital from 2012 to 2018 was conducted. The Kaplan-Meier method was used for survival analysis. The main endpoints of the study were locoregional control (LRC) and cancer specific survival (CSS). Results A total of 142 eligible cases were included,with a median BED10100Gy (100-132Gy). The median age was 75.6 years (47.2-89.0 years),among which 75 patients were aged (greater than or equal to 75 years old). The median follow-up time was 31.0 months,for patients< 75 years old and patients ≥ 75 years old. The 5-year LRC were 84.5% and 95.8% respectively,5-year CSS were 72.4% and 78.6% respectively,for patients< 75 years old and elderly patients. The systemic response was mild during treatment,no grade 4-5 adverse events occurred in all patients. The main acute side effect was radiation pneumonitis (RP) below grade 3. Grade 2 RP appeared in 14 patients (9.9%) after SBRT where grade 3 RP occurred in 2(1.4%). There was no treatment-related mortality in the SBRT group. Conclusions SBRT is a safe and effective treatment for early primary lung cancer with satisfactory rates of LRC and CSS in 5 years and mild complication,which is similar to previous reports.
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
Dong Baiqiang
Wang Jin
Xu Yujin
Hu Xiao
Du Xianghui
Shan Guoping
Shao Kainan
Bai Xue
Chen Ming
Key wordsLung neoplasms/stereotactic body radiotherapy      Treatment outcomes     
Received: 25 March 2019     
Fund:Zhejiang Public Welfare Fund (2017C33092)
Corresponding Authors: Chen Ming,Email:chenming@zjcc.org.cn   
Cite this article:   
Dong Baiqiang,Wang Jin,Xu Yujin et al. Experience and efficacy of SBRT for lung cancer:an analysis of 142 patients[J]. Chinese Journal of Radiation Oncology, 2020, 29(6): 416-420.
Dong Baiqiang,Wang Jin,Xu Yujin et al. Experience and efficacy of SBRT for lung cancer:an analysis of 142 patients[J]. Chinese Journal of Radiation Oncology, 2020, 29(6): 416-420.
URL:  
http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20190325-00107     OR     http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2020/V29/I6/416
  Copyright © 2010 Editorial By Chinese Journal of Radiation Oncology
Support by Beijing Magtech Co.ltd  support@magtech.com.cn